Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin- tazobactam regimens

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 11, 1997, Pages 2511-2517

  Occhipinti, Donna J ^a,b   Pendland, Susan L ^a   Schoonover, Lori L ^a,c   Rypins, Eric B ^a   Danziger, Larry H ^a   Rodvold, Keith A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM;

ADULT; ANTIBIOTIC THERAPY; ANTIBODY TITER; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BACTEROIDES FRAGILIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESCHERICHIA COLI; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; KLEBSIELLA PNEUMONIAE; MALE; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; PREDICTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 0030694701     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.11.2511     Document Type: Article

References (34)

1. Barriere, S. L., E. Ely, J. E. Kapusnik, and J. G. Gambertoglio. 1985. Analysis of a new method for assessing activity of combinations of antimicrobials: area under the bactericidal curve. J. Antimicrob. Chemother. 16: 49-59.
2. Batra, V. K., J. A. Morrison, K. C. Lasseter, and V. A. Joy. 1979. Piperacillin kinetics. Clin. Pharmacol. Ther. 26:41-59.
3. Bauer, L. A., and M. Gibaldi. 1983. Computation of model-independent pharmacokinetic parameters during multiple dosing. J. Pharm. Sci. 72:978-979.
4. Bergan, T., and J. D. Williams. 1982. Dose dependence of piperacillin pharmacokinetics. Chemotherapy 28:153-159.
5. Bolton, S. 1984. Experimental design in clinical trials, p. 362-404. In S. Bolton (ed.), Pharmaceutical statistics: practical and clinical applications. Marcel Dekker, Inc., New York, N.Y.
6. Brismar, B., A. S. Malmborg, G. Tunevall, B. Wretlind, L. Bergman, L. Mentzing, and P. O. Nystrom. 1992. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections. Antimicrob. Agents Chemother. 36:2766-2773.
7. Cheung, W. K., D. S. Greene, O. Kuye, K. Shin, A. P. Tonelli, A. Houston, and M. Hibberd. 1988. Pharmacokinetics of YTR 830 and piperacillin after intravenous coadministration, abstr. 159. In Program and abstracts of the 6th Mediterranean Congress of Chemotherapy, 1988.
8. Chow, J. W., M. J. Fine, D. M. Shlaes, J. P. Quinn, D. C. Hooper, M. P. Johnson, and R. Ramphal. 1991. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann. Intern. Med. 115:585-590.
9. Craig, W. A. 1995. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 22:89-96.
10. Echols, R., M. P. Weinstein, B. O'Keeffe, A. Shah, and A. H. Heller. 1994. Comparative crossover assessment of serum bactericidal activity and pharmacokinetics of ciprofloxacin and ofloxacin. J. Antimicrob. Chemother. 33: 111-118.
11. Eliopoulos, G. M., K. Klimm, M. J. Ferraro, G. A. Jacoby, and R. C. Moellering. 1989. Comparative in vitro activity of piperacillin combined with beta-lactamase inhibitor tazobactam (YTR 830). Diagn. Microbiol. Infect. Dis. 12:481-488.
12. Fass, R. J., and R. B. Prior. 1989. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate. Antimicrob. Agents Chemother. 33:1268-1274.
13. Flaherty, J. F., S. L. Barriere, J. Mordenti, and J. G. Gambertoglio. 1987. Effect of dose on pharmacokinetics and serum bactericidal activity of mezlocillin. Antimicrob. Agents Chemother. 31:895-898.
14. Hyatt, J. M., D. E. Nix, and J. J. Schentag. 1994. Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar. Antimicrob. Agents Chemother. 38:2730-2737.
15. Jacobs, M. R., S. C. Aronoff, S. Johenning, D. M. Shlaes, and S. Yamabe. 1986. Comparative activities of the β-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined β-lactamase-producing aerobic gram-negative bacilli. Antimicrob. Agents Chemother. 29:980-985.
16. Johnson, C. A., C. E. Halstenson, J. S. Kelloway, B. E. Shapiro, S. W. Zimmerman, A. Tonell, and R. Faulkner. 1992. Single dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease. Clin. Pharmacol. Ther. 51:32-41.
17. Kinzig, M., F. Sörgel, B. Brismar, and C. E. Nord. 1992. Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery. Antimicrob. Agents Chemother. 36:1997-2004.
18. Kuck, N. A., N. V. Jacobus, P. J. Petersen, W. J. Weiss, and R. T. Testa. 1989. Comparative in vitro and in vivo activities of piperacillin combined with the β-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Antimicrob. Agents Chemother. 33:1964-1969.
19. Metropolitan Life Foundation. 1983. Metropolitan height and weight tables. Stat. Bull. Metrop. Life Insur. Co. 64:1-9.
20. Mouton, Y., O. Leroy, C. Beuscart, C. Chidiac, E. Senneville, and F. Ajana. 1993. Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections. J. Antimicrob. Chemother. 31(Suppl. A):S87-S95.
21. National Committee for Clinical Laboratory Standards. 1992. Methodology for the serum bactericidal test. Tentative guideline. NCCLS document M21-T, vol. 12, no. 18. National Committee for Clinical Laboratory Standards, Villanova, Pa.
22. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically, 3rd ed. Approved standard. NCCLS document M7-A3, vol. 13, no. 25. National Committee for Clinical Laboratory Standards, Villanova, Pa.
23. Nicolau, D. P., C. H. Nightingale, M. A. Banevicius, Q. Fu, and R. Quintiliani. 1996. Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections. Antimicrob. Agents Chemother. 40:61-64.
24. Ocampo, A. P., K. D. Hoyt, N. Wadgaonkar, A. H. Carver, and C. V. Puglisi. 1989. Determination of tazobactam and piperacillin in human plasma, serum, bile and urine by gradient elution reversed-phase high-performance liquid chromatography. J. Chromatogr. 496:167-179.
25. Quinn, J. P., D. Miyashiro, D. Sahm, R. Flamm, and K. Bush. 1989. Novel plasmid-mediated β-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 33:1451-1456.
26. Schentag, J. J., D. E. Nix, and M. H. Adelman. 1991. Mathematical examination of dual individualization principles (I): relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP Ann. Pharmacother. 25:1050-1057.
27. Schoonover, L. L., D. J. Occhipinti, K. A. Rodvold, and L. H. Danziger. 1995. Piperacillin-tazobactam: a new beta-lactam-lactamase inhibitor combination. Ann. Pharmacother. 29:501-514.
28. Stobberingh, E. E. 1990. In vitro effect of YTR 830 (tazobactam) in plasmid and chromosomally mediated β-lactamases. Chemotherapy 36:209-214.
29. Sweet, R. L., S. Roy, S. Faro, W. F. O'Brien, J. S. Sanfilippo, M. Seidlin, and the Piperacillin/Tazobactam Study Group. 1994. Piperacillin and tazobactam versus clindamycin and gentamicin in the treatment of hospitalized women with pelvic infection. Obstet. Gynecol. 83:280-286.
30. Tan, J. S., R. M. Wishnow, D. A. Talan, F. P. Duncanson, C. W. Norden, and the Piperacillin/Tazobactam Skin and Skin Structure Study Group. 1993. Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. Antimicrob. Agents Chemother. 37: 1580-1586.
31. Tjandramaga, T. B., A. Mullie, R. Verbesselt, P. J. De Schepper, and L. Verbist. 1978. Piperacillin: human pharmacokinetics after intravenous and intramuscular administration. Antimicrob. Agents Chemother. 14:829-837.
32. Wagner, J. G. 1975. Fundamentals of clinical pharmacokinetics, p. 285-306. Drug Intelligence Publications Inc., Hamilton, Ill.
33. Welling, P. G., W. A. Craig, R. W. Bundtzen, F. Kwok, A. U. Gerber, and P. O. Madsen. 1983. Pharmacokinetics of piperacillin in subjects with various degrees of renal function. Antimicrob. Agents Chemother. 23:881-887.
34. Wise, R., M. Logan, M. Cooper, and J. M. Andrews. 1991. Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Antimicrob. Agents Chemother. 35:1081-1084.